查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029年全球地中海贫血症市场规模研究与预测，按治疗类别（铁螯合药物）、按管道（基因治疗）和区域分析。
市场调查报告书
商品编码
1269584

2022-2029年全球地中海贫血症市场规模研究与预测，按治疗类别（铁螯合药物）、按管道（基因治疗）和区域分析。

Global Thalassemia Market Size study & Forecast, by Therapeutic Class (Iron Chelating Drugs), by Pipeline (Gene Therapy) and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021年，全球地中海贫血症市场价值约为25.8亿美元，预计在2022-2029年的预测期内将以超过5%的健康增长率增长。根据美国疾病控制和预防中心（Centers for Disease Control and Prevention）的说法 - 地中海贫血症可被定义为一种遗传性血液疾病，当身体不能制造足够的血红蛋白时就会引起。血红蛋白是红血球的一个重要组成部分。地中海贫血是一种可以治疗的疾病，通过输血和螯合疗法可以得到很好的控制。与地中海贫血有关的体征和症状有不同类型，包括疲劳。虚弱，皮肤苍白或发黄，面部骨骼畸形，生长缓慢，腹部肿胀，以及尿液发黑等等。血液病发病率的增加和越来越多地采用输血和铁螯合疗法是推动市场增长的关键因素。

血液病患病率的增加有助于全球地中海贫血症市场的增长。例如，根据印度儿科学会（IPA）的估计，截至2021年，全球受地中海贫血影响的儿童总发病率中约有10%，每8个地中海贫血携带者中就有1个生活在印度。此外，根据世界卫生组织（WHO）的估计 - β-地中海贫血症影响了世界人口的2.9%。另外，发展中地区不断增长的医疗保健行业和越来越多的血液疾病临床试验将在预测期内为市场创造有利的增长前景。然而，在2022-2029年的预测期内，与地中海贫血症治疗相关的高成本抑制了市场增长。

全球地中海贫血症市场研究的主要地区包括亚太地区、北美、欧洲、拉丁美洲和世界其他地区。由于地中海贫血症的发病率不断增加，以及该地区卫生基础设施的支出增加，北美在收入方面主导了市场。而亚太地区在预测期内预计将以最高的复合年增长率增长，原因是诸如老年人和目标人群的增加，血液相关疾病发病率的增长，以及合同制造组织在该地区的快速扩张。

该研究的目的是确定近年来不同领域和国家的市场规模，并对未来几年的价值进行预测。该报告旨在将研究涉及的国家内的行业的质量和数量方面都纳入其中。

该报告还提供了关于关键方面的详细信息，如驱动因素和挑战，这将确定市场的未来增长。此外，它还纳入了微观市场的潜在机会，供利益相关者投资，并详细分析了竞争格局和主要参与者的产品。.

目录

第一章：执行摘要

  • 市场简介
  • 2019-2029年全球及细分市场的估计和预测
    • 2019-2029年地中海贫血症市场，按地区划分
    • 2019-2029年地中海贫血症市场，按治疗类别划分
    • 2019-2029年地中海贫血症市场，按管线划分
  • 主要趋势
  • 估算方法
  • 研究假设

第二章：全球地中海贫血症市场的定义和范围

  • 本研究的目的
  • 市场定义和范围
    • 研究的范围
    • 行业发展
  • 研究考虑的年份
  • 货币兑换率

第三章：全球地中海贫血症市场动态

  • 地中海贫血症市场影响分析（2019-2029）。
    • 市场驱动力
      • 血液疾病的发病率越来越高
      • 越来越多地采用输血和铁螯合疗法
    • 市场挑战
      • 与地中海贫血症治疗有关的高成本
    • 市场机会
      • 发展中地区的医疗保健行业不断增长
      • 血液疾病的临床试验越来越多

第四章：全球地中海贫血症市场行业分析

  • 波特五力模型
    • 供应商的议价能力
    • 买方的讨价还价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争性的竞争
  • 波特五力模型的未来方法（2019-2029年）
  • PEST分析
    • 政治因素
    • 经济
    • 社会
    • 技术
  • 最佳投资机会
  • 最佳策略
  • 行业专家展望
  • 分析师建议和结论

第五章：风险评估：COVID-19的影响

  • 评估COVID-19对行业的整体影响
  • COVID-19前和COVID-19后的市场情况

第六章：全球地中海贫血症市场，按治疗类别划分

  • 市场简介
  • 按治疗类别分類的全球地中海贫血症市场，性能-潜力分析
  • 2019-2029年全球地中海贫血症市场按治疗类别的估计和预测
  • 地中海贫血症市场，細項分析
    • 铁质螯合药物

第7章 ：全球地中海贫血症市场，按管线划分

  • 市场简介
  • 全球地中海贫血症市场的管线、性能 - 潜力分析
  • 2019-2029年全球地中海贫血症市场按管道的估计和预测
  • 地中海贫血症市场，次级细分市场分析
    • 基因治疗

第八章：全球地中海贫血症市场，区域分析

  • 地中海贫血症市场，区域市场简介
  • 北美洲
    • 美国
      • 2019-2029年治疗类别细分估计和预测
      • 2019-2029年管线分类估计和预测
    • 加拿大
  • 欧洲地中海贫血症市场简介
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区地中海贫血症市场简介
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉丁美洲地中海贫血症市场简介
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 世界其他地区

第九章：竞争情报

  • 顶级市场战略
  • 公司简介
    • Bluebird Bio Inc.
      • 关键信息
      • 概况
      • 财务（取决于数据的可用性）
      • 产品摘要
      • 近期发展情况
    • Acceleron Pharma, Inc.
    • Celgene Corporation
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Gamida Cell
    • Kiadis Pharma
    • La Jolla Pharmaceutical Company
    • IONIS Pharmaceuticals
    • Novartis AG

第十章 ：研究过程

  • 研究过程
    • 资料探勘
    • 数据分析
    • 市场评估
    • 验证
    • 出版
  • 研究属性
  • 研究假设

Global Thalassemia Market is valued approximately USD 2.58 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2022-2029. According to Centers for Disease Control and Prevention - Thalassemia can be defined as an inherited blood disorder caused when the body doesn't make enough hemoglobin. Hemoglobin is an important part of red blood cells. Thalassemia is a treatable disorder that can be well-managed with blood transfusions and chelation therapy. There are different types of signs and symptoms associated with thalassemia including Fatigue. Weakness, Pale or yellowish skin, Facial bone deformities, Slow growth, Abdominal swelling., and Dark urine among others. The increasing prevalence of blood disorders and growing adoption of blood transfusion and iron chelation therapies are key factors driving the market growth.

The increasing prevalence of blood disorders is contributing towards the growth of the Global Thalassemia Market. For instance - according to Indian Academy of Pediatrics (IPA) estimates - as of 2021, approximately 10% of the total world incidence of thalassemia-affected children and one in eight of thalassemia carriers live in India. Additionally, as per World Health organization (WHO) estimates - Beta-thalassemia affects 2.9% of the world's population. Also, growing healthcare industry in developing regions and increasing number of clinical trials for blood disorders would create lucrative growth prospectus for the market over the forecast period. However, the high cost associated with Thalassemia treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Thalassemia Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the growing incidences of thalassemia and rise in spending in health infrastructure in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and growing incidences of blood related disorders as well as rapid expansion of contract manufacturing organizations in the region.

Major market player included in this report are:

  • Bluebird Bio Inc.
  • Acceleron Pharma, Inc.
  • Celgene Corporation
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Gamida Cell
  • Kiadis Pharma
  • La Jolla Pharmaceutical Company
  • IONIS Pharmaceuticals
  • Novartis AG

Recent Developments in the Market:

  • In August 2022, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy intended for the treatment of adult and pediatric patients affected by beta-thalassemia.

Global Thalassemia Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered Therapeutic Class, Pipeline, Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Therapeutic Class:

  • Iron Chelating Drugs

By Pipeline:

  • Gene Therapy

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Thalassemia Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Thalassemia Market, by Therapeutic Class, 2019-2029 (USD Billion)
    • 1.2.3. Thalassemia Market, by Pipeline, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Thalassemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Thalassemia Market Dynamics

  • 3.1. Thalassemia Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of blood disorders
      • 3.1.1.2. Growing adoption of blood transfusion and iron chelation therapies
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost associated with treatment of Thalassemia
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing healthcare industry in developing regions
      • 3.1.3.2. Increasing number of clinical trials for blood disorders

Chapter 4. Global Thalassemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Thalassemia Market, by Therapeutic Class

  • 6.1. Market Snapshot
  • 6.2. Global Thalassemia Market by Therapeutic Class, Performance - Potential Analysis
  • 6.3. Global Thalassemia Market Estimates & Forecasts by Therapeutic Class 2019-2029 (USD Billion)
  • 6.4. Thalassemia Market, Sub Segment Analysis
    • 6.4.1. Iron Chelating Drugs

Chapter 7. Global Thalassemia Market, by Pipeline

  • 7.1. Market Snapshot
  • 7.2. Global Thalassemia Market by Pipeline, Performance - Potential Analysis
  • 7.3. Global Thalassemia Market Estimates & Forecasts by Pipeline 2019-2029 (USD Billion)
  • 7.4. Thalassemia Market, Sub Segment Analysis
    • 7.4.1. Gene Therapy

Chapter 8. Global Thalassemia Market, Regional Analysis

  • 8.1. Thalassemia Market, Regional Market Snapshot
  • 8.2. North America Thalassemia Market
    • 8.2.1. U.S. Thalassemia Market
      • 8.2.1.1. Therapeutic Class breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Pipeline breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Thalassemia Market
  • 8.3. Europe Thalassemia Market Snapshot
    • 8.3.1. U.K. Thalassemia Market
    • 8.3.2. Germany Thalassemia Market
    • 8.3.3. France Thalassemia Market
    • 8.3.4. Spain Thalassemia Market
    • 8.3.5. Italy Thalassemia Market
    • 8.3.6. Rest of Europe Thalassemia Market
  • 8.4. Asia-Pacific Thalassemia Market Snapshot
    • 8.4.1. China Thalassemia Market
    • 8.4.2. India Thalassemia Market
    • 8.4.3. Japan Thalassemia Market
    • 8.4.4. Australia Thalassemia Market
    • 8.4.5. South Korea Thalassemia Market
    • 8.4.6. Rest of Asia Pacific Thalassemia Market
  • 8.5. Latin America Thalassemia Market Snapshot
    • 8.5.1. Brazil Thalassemia Market
    • 8.5.2. Mexico Thalassemia Market
    • 8.5.3. Rest of Latin America Thalassemia Market
  • 8.6. Rest of The World Thalassemia Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Bluebird Bio Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Acceleron Pharma, Inc.
    • 9.2.3. Celgene Corporation
    • 9.2.4. GlaxoSmithKline plc
    • 9.2.5. Incyte Corporation
    • 9.2.6. Gamida Cell
    • 9.2.7. Kiadis Pharma
    • 9.2.8. La Jolla Pharmaceutical Company
    • 9.2.9. IONIS Pharmaceuticals
    • 9.2.10. Novartis AG

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Thalassemia Market, report scope
  • TABLE 2. Global Thalassemia Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Thalassemia Market estimates & forecasts by Therapeutic Class 2019-2029 (USD Billion)
  • TABLE 4. Global Thalassemia Market estimates & forecasts by Pipeline 2019-2029 (USD Billion)
  • TABLE 5. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Thalassemia Market
  • TABLE 70. List of primary sources, used in the study of global Thalassemia Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Thalassemia Market, research methodology
  • FIG 2. Global Thalassemia Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Thalassemia Market, key trends 2021
  • FIG 5. Global Thalassemia Market, growth prospects 2022-2029
  • FIG 6. Global Thalassemia Market, porters 5 force model
  • FIG 7. Global Thalassemia Market, pest analysis
  • FIG 8. Global Thalassemia Market, value chain analysis
  • FIG 9. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Thalassemia Market, regional snapshot 2019 & 2029
  • FIG 15. North America Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Thalassemia Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable